SELLAS Life Sciences Group, Inc. (FRA:RXK3)

Germany flag Germany · Delayed Price · Currency is EUR
3.210
-0.155 (-4.61%)
Last updated: Jan 9, 2026, 10:32 AM CET
241.49%
Market Cap423.70M
Revenue (ttm)n/a
Net Income (ttm)-22.11M
Shares Outn/a
EPS (ttm)-0.24
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume4,852
Open3.135
Previous Close3.365
Day's Range3.135 - 3.210
52-Week Range0.877 - 4.495
Betan/a
RSI63.14
Earnings DateMar 18, 2026

About FRA:RXK3

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembroli... [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Angelos Stergiou
Employees 15
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol RXK3
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.